Efficacy and Safety of GLP-1 first therapy compared with Insulin GLP-1 relay therapy in type 2 diabetes with inadequate glucose control: a randomized, open-label, multicenter parallel-group study - Direct comparison of GLP-1 first therapy and Insulin-GLP-1 relay therapy.

Kanazawa university Department of Disease Control and Homeostasis0 个研究点目标入组 120 人开始时间: 2014年6月2日最近更新: 2023年10月17日

适应症

试验速览

阶段: 未知
状态: 已完成
发起方
入组人数: 120

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

The GLP-1 receptor agonist is overall effective without prior glycemic control with insulin in participants with poorly controlled type 2 diabetes. However, in participants with insulinopenic type 2 diabetes, prior glycemic control with insulin may overcome glucose toxicity-induced GLP-1 resistance.

研究设计

研究类型: Interventional

入排标准

年龄范围: 20years-old 至 ot applicable（—）
性别: All

入选标准

未提供

排除标准

•Patients who have history of serious hypersensitivity to Liraglutide, Exenatide, Lixisenatide and insulin degludec. Patients with type 1 diabetes or impaired glucose tolerance due to other specific mechanisms or diseases or gestational diabetes. Patients with diabetic ketoacidosis Patients who have history of severe hypoglycemia with coma or loss of consciousness Patients with serious infection or severe traumatic injury Patients with steroids as unstable daily dose. Patients with unstable hypertension with medication like systolic blood pressure above 160 mmHg or diastolic blood pressure above 100mmHg. Patients with severe hepatic failure or renal failure or cardiac disorder and identified inappropriate patients for this study by the physicians in charge. Patients with proliferative retinopathy (excluding old proliferative retinopathy without necessary of intervention) and patients with maculopathy with necessary of intervention. Patients who have history of malignancy Excluding following patients Patients who have history of cured basal cell tumor by appropriate treatment or uterocervical carcinoma in situ Patients who have history of malignancy more than 1 year before and also have no reappearance Patients who onset malignancy during the period of the study. Patients with severe complication and identified inappropriate patients for this study by the physicians in charge. The pregnant women or women having possibilities of being pregnant and the women with breast-feeding Other patients who are identified inappropriate patients for this study by the physicians in charge.

研究者

发起方

Kanazawa university Department of Disease Control and Homeostasis

相似试验

进行中（未招募）

1 期

GLP-1 and hyperoxia for organ protection in heart surgeryWe investigate the efficacy of commercially available GLP-1 analog for reducing organ damage in patients undergoing heart surgery (i.e. coronary artery bypass grafting and/or aortic valve replacement).In addition we investigate the efficacy of restrictive versus liberal oxygenation (i.e. FiO2 50% versus FiO2 100%) for reducing organ damage during weaning after heart surgery. The study is a two-by-two factorial designed randomized clinical trial.MedDRA version: 20.0Level: LLTClassification code 10008937Term: Chronic ischemic heart disease, unspecifiedSystem Organ Class: 100000011627

EUCTR2015-003050-41-DKRigshospitalet

已完成

不适用

GLP-1 analogue therapy on glycemic control in patients undergoing cardiac surgerytype2 diabetes

JPRN-UMIN000008003GLOLIA investigation group70

已完成

不适用

The efficacy of GLP-1 receptor agonist on glycemic control in type 2 diabetes with inadequate DPP-4 inhibitor therapy.type 2 diabetes

JPRN-UMIN000006959Department of Metabolism and Endocrinology, Juntendo Graduate University of Medicine90

已完成

不适用

ong-term efficacy and safety of the GLP-1 receptor agonist liraglutide in Japanese patients with type 2 diabetes mellitus.Type 2 Diabetes mellitus

JPRN-UMIN000037603akakinen clinic1,000

招募中

不适用

Observation of using GLP-1 receptor agonist for wellness of brain activity in type 2 diabetes patients with mild cognitive impairment

JPRN-UMIN000030840Ogawa Red Cross Hospital50